ArticleArthritis research & therapy2007
Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.
Article in Arthritis research & therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- A 23-Plex Cytokine/Chemokine Analysis Identifies TNFRII, MMP-8, and sIL-1RII as Potential Biomarkers for Systemic Sclerosis.Biomedicines · 2025Article
- Treatment with mycophenolate mofetil is associated with improved nailfold vasculature in systemic sclerosis.Rheumatology (Oxford, England) · 2024Article
- Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension.Rheumatology (Oxford, England) · 2021Article
- Type III, IV, and VI Collagens Turnover in Systemic Sclerosis - a Longitudinal Study.Scientific reports · 2020Article
- [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- Personalised medicine in interstitial lung diseases: Number 6 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Current perspectives on the role of CD8+ T cells in systemic sclerosis.Immunology letters · 2018Review
- Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis.Clinical rheumatology · 2017Article
- Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice.Journal of hepatology · 2016Article
- Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic Sclerosis.PloS one · 2016Article
- Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.Pulmonary circulation · 2013Article
- Brain interleukin-15 in neuroinflammation and behavior.Neuroscience and biobehavioral reviews · 2013Review
- Application of biomarkers to clinical trials in systemic sclerosis.Current rheumatology reports · 2012Review
- Circulating biomarkers of interstitial lung disease in systemic sclerosis.International journal of rheumatology · 2012Article
- Systemic sclerosis with hemoptysis and a huge lung cavity.Clinics and practice · 2011Article
- Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.Molecular & cellular proteomics : MCP · 2011Article
- Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.British journal of pharmacology · 2011Article
- Biomarkers in systemic sclerosis.Biomarkers in medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P < 0.01). Serum IL-15 levels correlated with impaired lung function, assessed both by the vital capacity (P < 0.05) and by the carbon monoxide diffusion capacity (P < 0.05). The association between IL-15 and the vital capacity remained after multiple linear regression analysis. Patients with intermediate serum IL-15 levels had a higher prevalence of increased systolic pulmonary pressure compared with patients with either low or high serum IL-15 levels (P < 0.05). Moreover, increased serum IL-15 levels were associated with a reduced nailfold capillary density in multivariable logistic regression analysis (P < 0.01). Serum IL-15 levels also correlated inversely with the systolic blood pressure (P < 0.01). We conclude that IL-15 is associated with fibrotic as well as vascular lung disease and vasculopathy in early SSc. IL-15 may contribute to the pathogenesis of SSc. IL-15 could also be a candidate biomarker for pulmonary involvement and a target for therapy in SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.